多肽龙头翰宇药业出海再迎里程碑

中国科技新闻网03-15

3月12日,全球化医疗器械创新龙头碧迪医疗(BDX)到访翰宇药业,双方就“共同加速多肽药物国际化进程”的主题展开了深度交流,涉及翰宇药业利拉鲁肽注射剂产品美国市场商业化备货所需的注射笔供应保障,以及司美格鲁肽等未来GLP-1产品的合作规划等。据了解,碧迪医疗是一家全球化的医疗技术公司,主要从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2419941549?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-15 16:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2419941549","market":"us","top_or_hot":-1,"title":"多肽龙头翰宇药业出海再迎里程碑","media":"中国科技新闻网","content":"<div>\n<p>3月12日,全球化医疗器械创新龙头碧迪医疗(BDX)到访翰宇药业,双方就“共同加速多肽药物国际化进程”的主题展开了深度交流,涉及翰宇药业利拉鲁肽注射剂产品美国市场商业化备货所需的注射笔供应保障,以及司美格鲁肽等未来GLP-1产品的合作规划等。据了解,碧迪医疗是一家全球化的医疗技术公司,主要从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>多肽龙头翰宇药业出海再迎里程碑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n多肽龙头翰宇药业出海再迎里程碑\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-15 16:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b><strong>中国科技新闻网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月12日,全球化医疗器械创新龙头碧迪医疗(BDX)到访翰宇药业,双方就“共同加速多肽药物国际化进程”的主题展开了深度交流,涉及翰宇药业利拉鲁肽注射剂产品美国市场商业化备货所需的注射笔供应保障,以及司美格鲁肽等未来GLP-1产品的合作规划等。据了解,碧迪医疗是一家全球化的医疗技术公司,主要从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b","article_id":"2419941549","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2419941549","pubTimestamp":1710491152,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月12日,全球化医疗器械创新龙头碧迪医疗到访翰宇药业,双方就“共同加速多肽药物国际化进程”的主题展开了深度交流,涉及翰宇药业利拉鲁肽注射剂产品美国市场商业化备货所需的注射笔供应保障,以及司美格鲁肽等未来GLP-1产品的合作规划等。事实上,正如翰宇药业董事长曾少贵所说,公司国际化战略布局已进入收获期,利拉鲁肽、司美格鲁肽、醋酸格拉替雷、西曲瑞克等产品的以美国为首的海外注册申报工作均顺利推进。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4082":"医疗保健设备","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4588":"碎股","BK4504":"桥水持仓","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","BDX":"碧迪医疗","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC"},"translate_title":"Hanyu Pharmaceutical, the leader of polypeptide, went to sea to meet the milestone again","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":0.9},"content_text":"3月12日,全球化医疗器械创新龙头碧迪医疗(BDX)到访翰宇药业,双方就“共同加速多肽药物国际化进程”的主题展开了深度交流,涉及翰宇药业利拉鲁肽注射剂产品美国市场商业化备货所需的注射笔供应保障,以及司美格鲁肽等未来GLP-1产品的合作规划等。据了解,碧迪医疗是一家全球化的医疗技术公司,主要从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品的开发、制造和销售。目前市值近700亿美元,在全球各国均设有分支机构。翰宇药业作为国内多肽药物制造领导企业,深耕多肽药物领域26年,2024年在国际化发展的道路上迎来了巨大收获,伴随近几年GLP-1市场爆发式的增长,翰宇药业GLP-1原料药与利拉鲁肽制剂已经屡获美国大客户订单认可,订单合计金额超3亿。事实上,正如翰宇药业董事长曾少贵所说,公司国际化战略布局已进入收获期,利拉鲁肽、司美格鲁肽、醋酸格拉替雷、西曲瑞克等产品的以美国为首的海外注册申报工作均顺利推进。碧迪医疗作为全球知名的医疗器械创新公司,如果双方能够深化合作关系,未来对双方将是双赢的局面。值得注意的是,,翰宇药业3月1日在投资者互动平台表示,公司GLP-1利拉鲁肽注射剂美国上市申请于2月29日收到了美国FDA的反馈通知,通知显示美国FDA就公司申报上市的GLP-1利拉鲁肽注射剂已无重大缺陷(即:生物等效性、免疫原性、杂质研究、稳定性等数据被官方认可),仅对标签说明书、质量标准方面反馈了微小调整意见。公司已根据美国FDA反馈,确认了整改的方案及计划,将尽快回复美国FDA,积极推进制剂上市申报的工作。公司利拉鲁肽原料药已经收到了美国FDA下发的利拉鲁肽原料药《firstAdequate Letter》,质量获得了美国FDA的认可,并且也收到了美国FDA关于利拉鲁肽原料药DMF的No further comments邮件通知,获得无进一步缺陷的审评结果。另外,GLP-1原料药美国大订单已进入陆续发货阶段,利拉鲁肽注射剂美国大订单正在全力备货,将按照约定交货期发出。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2419941549"}